KA/EN
Register
Medicines reference
Search
Search
Active substance

Hyaluronic acid

Favourites

Glycosaminoglycan (joint and eye lubricant). Registered in Georgia: 1 veterinary product. Forms: solution.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Hyaluronic acid
Dose Species Indication Route Frequency Source
30–50 mg per animal Dog, Cat Maintenance Intravenous every 3-9 days, 3-7 doses
Hyaluronan Bioveta SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Hyaluronan Bioveta 10 mg/ml solution for injection - current Czech authorisation and SPC
EU Veterinary Medicines Information / Czech authority, 2026
Before use

Safety information

Known Contraindications

  • Critical
    Do not use if hypersensitive to sodium hyaluronate or excipients.
    Sources: Czech SPC
  • Warning
    Do not give together with cationic antimicrobials (erythromycin, amoxicillin, cefquinome): hyaluronan precipitates with them.
    Sources: Czech SPC
Latin name
Hyaluronic acid
Georgian name
ჰიალურონის მჟავა
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 1 forms
Products
Hyaluronan Bioveta
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Hyaluronan Bioveta 10 mg/ml, Solution

sodium hyaluronate 10 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-authorised adjunctive IV treatment of non-infectious degenerative or inflammatory orthopaedic disease
7.0/10
Good
vetman assessment

Hyaluronan Bioveta

10 mg/ml, sodium hyaluronate 10 mg/ml, solution for injection
Assessed clinical scopeDog · Label-authorised adjunctive IV treatment of non-infectious degenerative or inflammatory orthopaedic disease · Intravenous
Care settingRepeated veterinarian-administered slow IV treatment with aseptic venous access, objective pain/function monitoring and multimodal orthopaedic care
vetman score 7.0/10 Good
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A transparent, authorised canine IV adjunct with a usable exact regimen, but mixed small-study efficacy and repeated venous treatment prevent a stronger place in multimodal orthopaedic care.

Regulatory and scientific credibility8.0/10

The exact 6 ml, 10 mg/ml formulation has current Georgian registration and a current Czech/EU authorisation covering dogs and cats, both routes, doses and safety. Independent exact-product outcome data remain limited.

Clinical efficacy6.5/10

Direct canine evidence is mixed: a small controlled TPLO trial found no significant synovial biomarker benefit, experimental work is mechanistic, and a recent 18-dog uncontrolled study suggests improvement. It supports an adjunctive role, not proven disease modification.

Safety and tolerability7.5/10

The exact label reports no known adverse effects and permits pregnancy/lactation, but repeated venous access, aseptic failure, hypersensitivity and limited target-species outcome surveillance remain. Hyaluronan-metabolism disorders warrant caution.

Clinical practicality5.5/10

The fixed 3–5 ml per-animal range avoids weight arithmetic, but 3–7 slow IV visits, venous access, response measurement, immediate vial discard and cationic-drug incompatibility create substantial veterinary workflow burden.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only for a diagnosed non-infectious orthopaedic condition within multimodal care. It is an adjunct, not a substitute for analgesia, weight management, rehabilitation or treatment of structural/infectious disease.
  • Dose is fixed per animal: 3–5 ml (30–50 mg) slowly IV, 3–7 administrations every 3–9 days. Do not convert this label range into mg/kg, inject intra-articularly or substitute another route.
  • Use aseptic technique. The preservative-free vial must be used immediately after first opening and all remainder discarded; never save, share or re-enter it for a later dose or patient.
  • Do not mix or administer concurrently with cationic antimicrobials such as erythromycin, amoxicillin or cefquinome because precipitation occurs. Reconcile the complete treatment plan and use a separated compatible regimen.
  • Record baseline pain, gait/function and concurrent therapy, then reassess objectively. Stop an ineffective course rather than assuming biomarker or mechanistic findings guarantee clinical benefit.
  • Avoid in hypersensitivity. Seek specialist advice or choose an alternative in known or suspected hyaluronan-metabolism disorders, including Shar-Pei cutaneous mucinosis.
  • Slow IV administration requires reliable venous access and observation for extravasation, hypersensitivity, infection and acute clinical change. Do not administer an opaque, contaminated, frozen or improperly stored solution.
  • The exact label permits use in pregnancy and lactation, but individual benefit–risk assessment remains appropriate where disease, co-medication or repeated exposure adds uncertainty.
  • Canine evidence supports only an adjunctive role and is limited in size and consistency. Do not describe this product as disease-modifying or broadly proven across every label indication.
  • Store below 25 °C, protect from light and freezing, check expiry and solution integrity, and prevent self-injection or eye/skin exposure. Accidental injection requires urgent medical advice.
Assessment sources
  1. Hyaluronan Bioveta SPC2026
  2. Hyaluronan exact2026
  3. Bonharen EU control2025
  4. Canine TPLO trial2006
  5. Canine OA mechanism2006
  6. Canine IV OA study2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Dog Label-authorised topical lubricant/support for keratitis, conjunctivitis/keratoconjunctivitis, KCS and corneal injury or ulcer within diagnosis-led ophthalmic care
6.7/10
Situational / acceptable
vetman assessment

Hyaluronan Bioveta

10 mg/ml, sodium hyaluronate 10 mg/ml, solution for injection
Assessed clinical scopeDog · Label-authorised topical lubricant/support for keratitis, conjunctivitis/keratoconjunctivitis, KCS and corneal injury or ulcer within diagnosis-led ophthalmic care · Into the eye
Care settingVeterinary-diagnosed ophthalmic treatment in clinic or at home, with sterile handling and scheduled ocular re-examination
vetman score 6.7/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A traceable authorised ocular lubricant with supportive canine KCS evidence, useful as an adjunct after diagnosis; it does not replace ulcer, infection or tear-deficiency treatment.

Regulatory and scientific credibility8.0/10

The exact 6 ml, 10 mg/ml formulation has current Georgian registration and a current Czech/EU authorisation covering dogs and cats, both routes, doses and safety. Independent exact-product outcome data remain limited.

Clinical efficacy5.5/10

A small prospective canine KCS study and clinical reviews support hyaluronate as tear-film/lubricant adjunct, but generic drops do not validate every broad exact-label ocular claim or replace cause-directed treatment.

Safety and tolerability7.0/10

Topical hyaluronate is generally well tolerated and the exact label reports no known adverse effects, but preservative-free vial contamination, ocular-surface worsening and delayed treatment of ulcer/infection remain clinically important; feline direct safety data are sparse.

Clinical practicality6.0/10

Drops are simple to administer and the broad 2–12-hour interval allows tailoring, but diagnosis, possible frequent dosing, 5–60-day duration, sterile technique and immediate discard of a 6 ml injection vial reduce practicality and increase wastage.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Confirm the ocular diagnosis and assess tear film, fluorescein staining, pressure and infection as indicated. This lubricant adjunct does not replace immunomodulatory, antimicrobial, ulcer or surgical treatment.
  • Instil 1–2 drops into the conjunctival sac every 2–12 hours for 5–60 days. Do not turn the broad range into indefinite treatment without scheduled response and ocular-surface recheck.
  • Use aseptic technique. The preservative-free vial must be used immediately after first opening and all remainder discarded; never save, share or re-enter it for a later dose or patient.
  • Do not mix or administer concurrently with cationic antimicrobials such as erythromycin, amoxicillin or cefquinome because precipitation occurs. Reconcile the complete treatment plan and use a separated compatible regimen.
  • Re-examine promptly for pain, blepharospasm, discharge, worsening opacity, melting, vision change or failure to improve. Never use topical corticosteroid on a corneal ulcer.
  • Avoid in hypersensitivity. Seek specialist advice or choose an alternative in known or suspected hyaluronan-metabolism disorders, including Shar-Pei cutaneous mucinosis.
  • Do not touch the eye or adnexa with the vial tip. Ocular pain or deterioration may indicate ulcer, infection, uveitis, glaucoma or another condition for which lubricant-only treatment is unsafe.
  • The exact label permits use in pregnancy and lactation, but individual benefit–risk assessment remains appropriate where disease, co-medication or repeated exposure adds uncertainty.
  • Canine evidence supports only an adjunctive role and is limited in size and consistency. Do not describe this product as disease-modifying or broadly proven across every label indication.
  • Store below 25 °C, protect from light and freezing, check expiry and solution integrity, and prevent self-injection or eye/skin exposure. Accidental injection requires urgent medical advice.
Assessment sources
  1. Hyaluronan Bioveta SPC2026
  2. Hyaluronan exact2026
  3. Canine carbomer-gel comparator2012
  4. Canine KCS review2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-authorised adjunctive IV treatment of non-infectious degenerative or inflammatory orthopaedic disease
6.1/10
Situational / acceptable
vetman assessment

Hyaluronan Bioveta

10 mg/ml, sodium hyaluronate 10 mg/ml, solution for injection
Assessed clinical scopeCat · Label-authorised adjunctive IV treatment of non-infectious degenerative or inflammatory orthopaedic disease · Intravenous
Care settingRepeated veterinarian-administered slow IV treatment with aseptic venous access, objective pain/function monitoring and multimodal orthopaedic care
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

Authorised and operationally defined for cats, but direct feline IV outcome evidence is absent; reserve for selected monitored cases rather than extrapolating canine benefit.

Regulatory and scientific credibility8.0/10

The exact 6 ml, 10 mg/ml formulation has current Georgian registration and a current Czech/EU authorisation covering dogs and cats, both routes, doses and safety. Independent exact-product outcome data remain limited.

Clinical efficacy4.0/10

The exact label authorises cats, but no direct feline IV clinical-outcome study was identified. Canine findings and regulatory acceptance cannot establish comparable feline efficacy.

Safety and tolerability7.0/10

The exact label reports no known adverse effects and permits pregnancy/lactation, but repeated venous access, aseptic failure, hypersensitivity and limited target-species outcome surveillance remain. Hyaluronan-metabolism disorders warrant caution.

Clinical practicality5.0/10

The fixed 3–5 ml per-animal range avoids weight arithmetic, but 3–7 slow IV visits, venous access, response measurement, immediate vial discard and cationic-drug incompatibility create substantial veterinary workflow burden.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only for a diagnosed non-infectious orthopaedic condition within multimodal care. It is an adjunct, not a substitute for analgesia, weight management, rehabilitation or treatment of structural/infectious disease.
  • Dose is fixed per animal: 3–5 ml (30–50 mg) slowly IV, 3–7 administrations every 3–9 days. Do not convert this label range into mg/kg, inject intra-articularly or substitute another route.
  • Use aseptic technique. The preservative-free vial must be used immediately after first opening and all remainder discarded; never save, share or re-enter it for a later dose or patient.
  • Do not mix or administer concurrently with cationic antimicrobials such as erythromycin, amoxicillin or cefquinome because precipitation occurs. Reconcile the complete treatment plan and use a separated compatible regimen.
  • Record baseline pain, gait/function and concurrent therapy, then reassess objectively. Stop an ineffective course rather than assuming biomarker or mechanistic findings guarantee clinical benefit.
  • Avoid in hypersensitivity. Seek specialist advice or choose an alternative in known or suspected hyaluronan-metabolism disorders, including Shar-Pei cutaneous mucinosis.
  • Slow IV administration requires reliable venous access and observation for extravasation, hypersensitivity, infection and acute clinical change. Do not administer an opaque, contaminated, frozen or improperly stored solution.
  • The exact label permits use in pregnancy and lactation, but individual benefit–risk assessment remains appropriate where disease, co-medication or repeated exposure adds uncertainty.
  • Feline use is label-authorised, but direct feline clinical-outcome evidence for this route was not identified. Do not infer the canine effect size or evidence confidence.
  • Store below 25 °C, protect from light and freezing, check expiry and solution integrity, and prevent self-injection or eye/skin exposure. Accidental injection requires urgent medical advice.
Assessment sources
  1. Hyaluronan Bioveta SPC2026
  2. Hyaluronan exact2026
  3. Bonharen EU control2025
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-authorised topical lubricant/support for keratitis, conjunctivitis/keratoconjunctivitis, KCS and corneal injury or ulcer within diagnosis-led ophthalmic care
6.0/10
Situational / acceptable
vetman assessment

Hyaluronan Bioveta

10 mg/ml, sodium hyaluronate 10 mg/ml, solution for injection
Assessed clinical scopeCat · Label-authorised topical lubricant/support for keratitis, conjunctivitis/keratoconjunctivitis, KCS and corneal injury or ulcer within diagnosis-led ophthalmic care · Into the eye
Care settingVeterinary-diagnosed ophthalmic treatment in clinic or at home, with sterile handling and scheduled ocular re-examination
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

Authorised for feline ocular support, but direct feline evidence is absent and sterile single-opening vial use is awkward; use only as a diagnosis-led adjunct with recheck.

Regulatory and scientific credibility8.0/10

The exact 6 ml, 10 mg/ml formulation has current Georgian registration and a current Czech/EU authorisation covering dogs and cats, both routes, doses and safety. Independent exact-product outcome data remain limited.

Clinical efficacy4.0/10

The exact label authorises topical feline use, but no direct feline outcome study for this formulation was identified. Canine KCS and generic lubricant evidence are indirect and do not establish efficacy across the broad feline ocular scope.

Safety and tolerability6.5/10

Topical hyaluronate is generally well tolerated and the exact label reports no known adverse effects, but preservative-free vial contamination, ocular-surface worsening and delayed treatment of ulcer/infection remain clinically important; feline direct safety data are sparse.

Clinical practicality5.0/10

Drops are simple to administer and the broad 2–12-hour interval allows tailoring, but diagnosis, possible frequent dosing, 5–60-day duration, sterile technique and immediate discard of a 6 ml injection vial reduce practicality and increase wastage.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Confirm the ocular diagnosis and assess tear film, fluorescein staining, pressure and infection as indicated. This lubricant adjunct does not replace immunomodulatory, antimicrobial, ulcer or surgical treatment.
  • Instil 1–2 drops into the conjunctival sac every 2–12 hours for 5–60 days. Do not turn the broad range into indefinite treatment without scheduled response and ocular-surface recheck.
  • Use aseptic technique. The preservative-free vial must be used immediately after first opening and all remainder discarded; never save, share or re-enter it for a later dose or patient.
  • Do not mix or administer concurrently with cationic antimicrobials such as erythromycin, amoxicillin or cefquinome because precipitation occurs. Reconcile the complete treatment plan and use a separated compatible regimen.
  • Re-examine promptly for pain, blepharospasm, discharge, worsening opacity, melting, vision change or failure to improve. Never use topical corticosteroid on a corneal ulcer.
  • Avoid in hypersensitivity. Seek specialist advice or choose an alternative in known or suspected hyaluronan-metabolism disorders, including Shar-Pei cutaneous mucinosis.
  • Do not touch the eye or adnexa with the vial tip. Ocular pain or deterioration may indicate ulcer, infection, uveitis, glaucoma or another condition for which lubricant-only treatment is unsafe.
  • The exact label permits use in pregnancy and lactation, but individual benefit–risk assessment remains appropriate where disease, co-medication or repeated exposure adds uncertainty.
  • Feline use is label-authorised, but direct feline clinical-outcome evidence for this route was not identified. Do not infer the canine effect size or evidence confidence.
  • Store below 25 °C, protect from light and freezing, check expiry and solution integrity, and prevent self-injection or eye/skin exposure. Accidental injection requires urgent medical advice.
Assessment sources
  1. Hyaluronan Bioveta SPC2026
  2. Hyaluronan exact2026
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Hyaluronic acid10 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Into the eye
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ჰიალურონან ბიოვეტა 10მგ/მლ
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 96/034/12-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Dog/cat IV: 3–5 ml per animal slowly, 3–7 administrations every 3–9 days. Ophthalmic: 1–2 drops every 2–12 hours for 5–60 days. These are separate route-specific regimens. Use immediately after opening and discard the remainder.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗